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P ercutaneous ablation therapies have been recog-nized as successful approaches in patients with 
hepatocellular carcinoma (HCC),  generally in patients 
with Child-Pugh class A or B liver function with ≤ 3 
tumors of ≤ 3 cm in diameter [1 , 2].
Radiofrequency ablation (RFA) is accepted as being 
as good as resection for Child-Pugh class A or B tumors 
of ≤ 3 cm in diameter [2].  In one study,  complete abla-
tion was achieved in > 99% of the RFA-treated patients 
with tumors ≤ 3 cm in diameter [3].  As a percutaneous 
ablation therapy,  RFA is regarded as superior to percu-
taneous ethanol injection (PEI),  as it achieves better 
overall survival,  overall recurrence and local tumor 
progression rates,  with no difference in the incidence of 
adverse events [4].
A Japanese nationwide survey of 12,968 patients 
who underwent surgical resection,  RFA,  and PEI 
showed that the 5-year recurrence rates in patients who 
received these treatments were 63.8%,  71.7%,  and 
76.9%,  respectively [5].  The clinical practice guidelines 
for HCC in Japan recommend resection as a first-line 
therapy for solitary HCC,  as is recommended in the 
American Association for the Study of Liver Diseases 
guidelines [2 , 6].  However,  as HCC usually occurs in 
cirrhosis patients,  the low rate of post-treatment com-
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Radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) is a promising method for controlling 
tumors,  although it does not entirely eliminate recurrence.  Oxidative stress is associated with the progression 
of hepatocarcinogenesis,  while also acting as an anticancer response.  The objective of the present study was to 
investigate the factors influencing post-RFA outcomes.  We recruited 235 newly diagnosed HCC patients who 
received RFA for single tumors.  The patients with recurrence were sub-grouped into early and segmental recur-
rence groups.  The characteristics of the sub-grouped patients were evaluated,  including by measuring oxidative 
stress marker reactive oxygen metabolites and antioxidant marker OXY-adsorbent tests.  The factors associated 
with poor survival were a high Child-Pugh score and early recurrence within 2 years in the same segment.  The 
patients who experienced recurrence within 2 years in the same segment showed a larger tumor diameter than 
did others.  According to a multivariate analysis,  the OXY values were also significantly low in these patients.  
In conclusion,  maintaining the antioxidant reservoir function with a high OXY value might be necessary to 
prevent early recurrence within the RFA-treated segment.
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plications with RFA is a strength of this local treatment 
[7].
Recurrence after local treatment can be divided into 
two patterns based on the time and lesion of recurrence.  
Early recurrence has been reported to arise mainly from 
intrahepatic metastasis and to have poor survival,  
whereas late recurrence is more likely to be of multi-
centric origin [8].  Even early-stage HCC patients have 
been shown to have a poor survival rate when they 
experience recurrence within one year after curative 
RFA [9].
Recurrence in the same segment after RFA is 
reported to be associated with a periportal location of 
the ablated tumor,  where complete eradication is diffi-
cult [10].  Given that resection is performed at the seg-
ment or lobe in which the tumor is located,  multifocal 
tumors localized in the sub-segment,  segment or lobe 
can be better controlled with resection than with RFA 
[11].  Early recurrence in anatomically the same seg-
ment is an important pattern of recurrence after RFA on 
which the tumor located segment remained.
It is necessary to identify the characteristics of 
recurrence after RFA in order to improve survival after 
RFA.  The tumor microenvironment has been shown to 
be a local recurrence factor.  Oxidative stress is cor-
related with hepatocarcinogenesis and can even induce 
a p53 mutation [12].  Reactive oxygen species (ROS) are 
a source of oxidative stress that are produced by free 
fatty acid metabolism in microsomes,  peroxisomes and 
mitochondria [13].  It has been reported that ROS 
induce the progression of HCC [14],  thereby inducing 
the synthesis and activation of a large number of cyto-
kines and growth factors [15].  Chronic inflammation 
due to viral hepatitis or lipid overload can induce ROS 
through microsomes,  peroxisomes,  and the activation 
or damaging of the mitochondrial energy metabolism 
pathway [13].  However,  such stress has recently been 
acknowledged to be part of the anticancer response,  
especially after tumor development [16].  There are sev-
eral markers for defining oxidative-stress-related condi-
tions in organs or serum.  The serum levels of dia-
chron-reactive oxygen metabolites (dROM,  Diacron,  
Italy),  a reactive oxygen metabolite marker have been 
shown to reflect circulating ROS [17 , 18].  The OXY-
adsorbent test (OXY,  Diacron,  Italy) has also been 
performed in order to evaluate the corresponding anti-
oxidative status [19].  In our previous analysis,  the 
dROM level increased with the progression from 
chronic hepatitis to HCC in hepatitis C virus (HCV)-
related diseases,  while the level of OXY decreased in 
HCC [20].  In patients with non-alcoholic fatty liver 
disease (NAFLD)-related HCC,  the OXY levels were 
lower than those in NAFLD patients without HCC [21].  
The oxidative stress-related condition in HCC is not well 
defined.
The objective of the present study was to investigate 
the balance between oxidative stress and the antioxida-
tive activity in patients with HCC who underwent radi-
cal RFA.  We investigated the possible correlations 
among dROM and OXY values and the clinical param-
eters and clinical course after local ablation of HCC.
Methods
Subjects. The study population included 235 
patients with newly diagnosed HCC who underwent 
radical RFA in our hospital.  The inclusion criteria were 
patients with solitary and hyper-vascular tumors with 
≤ 3 tumors of ≤ 3 cm in diameter who received radical 
RFA as the first-line treatment with a Child-Pugh class 
A or B liver function.  Neither vascular invasion nor 
metastasis was noted on dynamic computed tomogra-
phy (CT) or magnetic resonance imaging (MRI).  The 
exclusion criteria were patients with multiple tumors,  
hypo-vascular tumors,  tumors of > 3 cm in diameter,  
and recurrent tumors.  At three to four days after RFA,  
dynamic CT or MRI was performed to detect any resid-
ual lesions.  Additional RFA was performed until com-
plete ablation had been achieved.  After complete abla-
tion was obtained,  the patients were followed for 
recurrence using ultrasound or dynamic CT or dynamic 
MRI every three months.  The last observation date was 
April 2016,  before the direct-acting antiviral agent 
(DAA) for HCV had been widely used.  The median 
follow-up period was 1716 days.
The background characteristics of the patients are 
summarized in Table 1a.  The baseline liver diseases 
were diagnosed as HCV related chronic liver disease if 
the patients were positive for HCV antibody (Ab) in the 
serum,  as hepatitis B virus (HBV)-related chronic liver 
disease if the patients were positive for hepatitis B s 
antigen (HBs Ag) in the serum,  and as HBV + HCV-
related chronic liver disease if the patients were positive 
for both the HCV Ab and HBs Ag in the serum.
The patients were recruited at the Clinic of 
Gastroenterology and Hepatology,  Okayama University 
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Hospital,  from April 2001 to December 2013.  The 
study was approved by the Ethics Committee of 
Okayama University Graduate School of Medicine,  
Dentistry and Pharmaceutical Sciences (Approval num-
ber 1603-025).  Informed consent was obtained from all 
individual participants included in the study.
Blood sample collection and preparation. Fasting 
blood samples were collected from all patients before 
treatment.  The serum aliquots were stored at −80°C 
until subsequent analyses.  The obtained samples were 
used to obtain biochemical data,  including the serum 
levels of dROM and OXY.
Measurement of the serum dROM and OXY levels.
Measurement of the serum dROM levels was performed 
using a spectrophotometer (Diacron International,  
Grosseto,  Italy),  as reported previously [17].  The mea-
surement unit was the Carratelli unit (CARR U),  where 
1 CARR U corresponds to 0.08 mg/dl of hydrogen per-
oxide.  In order to determine the total serum antioxi-
dant capacity,  OXY was performed using a spectropho-
tometer (Diacron International) [19].  This test evaluates 
the capacity of serum to prevent the occurrence of 
massive oxidative activity in a hypochlorous acid 
(HClO) solution.  The total antioxidant capacity was 
expressed in terms of the HClO (μmol) consumed by 
1mL of sample (μmol HClO/mL).
Statistical analyses. Statistical analyses were con-
ducted using the JMP software package (Version 14;  
SAS Institute Inc.,  Cary,  NC,  USA).  Continuous vari-
ables were expressed as median values (interquartile 
range),  and the Mann-Whitney U-test or the chi-
squared test was used to compare parameters.  A Cox 
proportional hazard model was used for the univariate 
and multivariate analyses with stratification of the vari-
ables that were significantly correlated according to a 
univariate analysis.  Spearman’s rank correlation was 
used to evaluate the relationship between oxidative- 
stress-related markers and clinical parameters.  A mul-
tivariate logistic regression analysis was performed to 
define the parameters predictive of recurrence within 2 
years in the same segment.  Statistical significance was 
set at p < 0.05.
Results
Baseline characteristics of the patients. The clin-
ical characteristics of the patients are shown in Table 1a.  
HCV-related chronic liver disease was the most fre-
quent baseline liver disease.  The median values of 
oxidative stress-related markers were dROM 311 CARR 
U and OXY 314 μmol HClO/mL,  which were not 
markedly different from the healthy volunteer data in 
our previous report (dROM 306,  OXY 311) (Table 1b).  
The 5-year survival rate was 68%,  and the 5-year 
recurrence rate was 70% (Fig. 1).
Correlation between oxidative stress-related mark-
ers and clinical characteristics. To determine the 
characteristics of oxidative stress-related markers,  we 
investigated the correlation with clinical parameters 
(Table 2).  The dROM was positively correlated with the 
age and platelet count and negatively correlated with the 
prothrombin time international ratio.  The OXY was 
positively correlated with the platelet count and albu-
min levels and negatively correlated with the total bili-
rubin levels and Child-Pugh scores.
Factors associated with poor survival. The pre-
RFA factors associated with poor survival were analyzed 
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????? ??　 Patient characteristics
Number 235
Age (years) 69 (62-74)
Sex (Male : Female) 143 : 92
Baseline liver disease
　 HCV : HBV : HBV+HCV : others 178/26/4/27
Ferritin (ng/ml) 124 (63-271)
Platelet (104/μl) 10.4 (7.2-14.7)
CRP (mg/dl) 0.2 (0.07-0.48)
AST (U/L) 45 (33-61)
ALT (U/L) 38 (25-54)
T-Bil (mg/dl) 0.77 (0.59-1.09)
Albumin (g/dl) 3.7 (3.3-4.0)
Creatinine (mg/dl) 0.7 (0.6-0.9)
PT-INR 1.00 (0.94-1.06)
Child-Pugh Score 5 (5-6)
AFP (ng/ml) 11.4 (5.3-41.3)
AFP-L3 (%) 0.5 (0-5.4)
DCP (mAU/ml) 28 (18-65)
Tumor diameter (mm) 16 (13-20)
????? ??　 Oxidative stress-related markers
dROM (CARR U) 311 (270-356)
OXY (μmol HClO/mL) 314 (281-347)
Values were indicated as median (25-75 percentile) unless other-
wise noted.
HCV,  hepatitis C virus; HBV,  hepatitis B virus; CRP,  C-reactive 
protein; AST,  aspartate aminotransferase; ALT,  alanine amino-
transferase; T-Bil,  total bilirubin; PT-INR,  prothrombin time inter-
national ratio; AFP,  alpha fetoprotein; DCP,  des-gamma-carboxy 
prothrombin.
by a Cox proportional hazard model (Table 3).  The 
univariate analysis revealed that a high age,  non-HBV-
related baseline disease,  low platelet count,  low albu-
min level,  high Child-Pugh score,  high alpha-fetopro-
tein (AFP) level,  and low OXY level were associated 
with poor survival.  Given that the recurrence pattern 
could be divided into time-dependency and location- 
dependency,  we sub-grouped the early-recurrence 
patients into those who experienced recurrence within 
two years in the same segment and those who experi-
enced recurrence within 2 years in another segment.  
The recurrence pattern associated with poor survival of 
the patients was recurrence within 2 years in the same 
segment.  The multivariate Cox proportional hazard 
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????? ?　 The correlation between oxidative stress-related markers and clinical parameters
dROM OXY
Spearmanʼs rho p-value Spearmanʼs rho p-value
Age 0.297 <0.001＊ 0.052 0.522
Ferritin -0.105 0.227 -0.032 0.716
Platelet 0.172 0.032＊ 0.262 0.001＊
CRP 0.105 0.221 0.063 0.461
AST 0.108 0.180 0.001 0.987
ALT -0.016 0.843 0.082 0.312
T-Bil -0.146 0.070 -0.170 0.034＊
Albumin -0.017 0.835 0.285 <0.001＊
Creatinine -0.069 0.393 0.057 0.483
PT-INR -0.287 0.006＊ -0.197 0.062
Child-Pugh Score -0.038 0.638 -0.244 0.002＊
AFP 0.037 0.644 -0.103 0.203
AFP-L3 0.011 0.903 0.003 0.973
DCP 0.135 0.098 0.007 0.937
Tumor diameter 0.118 0.143 -0.012 0.887
CRP,  C-reactive protein; AST,  aspartate aminotransferase; ALT,  alanine aminotransferase; T-Bil,  total bilirubin; PT-INR,  prothrombin 
time international ratio; AFP,  alpha fetoprotein; DCP,  des-gamma-carboxy prothrombin.
＊Statistically significant data.
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???? ?　 The overall survival rate and recurrence rate of the patients.  (A) The 5-year survival rate was 68%.  (B) The 5-year recurrence 
rate was 70%.
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????? ?　 Pre-RFA and post- RFA recurrence style-related factors associated with poor survival
Cox regression analysis
Factors Univariate analysis Multivariate analysis
Odds ratio 95%CI p-value Odds ratio 95% CI p-value
Age (>69 years old) 1.55 1.04-2.32 0.032＊ 1.41 0.76-2.58 0.273
Male sex 1.01 0.67-1.52 0.971
non-HBV related 3.43 1.54-9.74 0.001＊ 1.75 0.71-5.28 0.236
Ferritin (>124 ng/ml) 1.39 0.90-2.17 0.137
Platelet (<10.4×104/μl) 2.18 1.46-3.31 <0.001＊ 1.55 0.84-2.95 0.166
CRP (>0.2 mg/dl) 0.90 0.58-1.40 0.644
AST (>45 U/L) 0.98 0.66-1.46 0.934
ALT (>38 U/L) 0.99 0.67-1.48 0.968
T-Bil (>0.77 mg/dl) 1.66 1.12-2.50 0.012
Albumin (<3.7 g/dl) 3.31 2.17-5.17 <0.001＊
Creatinine (>0.7 mg/dl) 1.33 0.90-2.00 0.158
PT-INR (>1.00) 2.07 1.09-4.02 0.027＊
Child-Pugh Score (>5) 3.28 2.16-5.06 <0.001＊ 3.03 1.57-6.10 <0.001＊
AFP (>10 ng/ml) 1.55 1.04-2.35 0.031＊ 1.28 0.72-2.30 0.392
AFP-L3 (>10%) 1.29 0.66-2.32 0.430
DCP (>40 mAU/ml) 1.23 0.83-1.83 0.302
Tumor diameter (>16 mm) 1.25 0.84-1.87 0.278
Oxidative stress-related markers
　dROM (>311 CARR U) 1.05 0.62-1.77 0.868
　OXY (<314 μmol HClO/mL) 1.88 1.10-3.24 0.022＊ 1.28 0.71-2.31 0.412
Recurrence style
　recurrence within 2 years in the same segment 2.36 1.48-3.65 <0.001＊ 2.04 1.09-3.68 0.026＊
　recurrence within 2 years in another segment 1.55 0.95-2.43 0.078
HBV,  hepatitis B virus; CRP,  C-reactive protein; AST,  aspartate aminotransferase; ALT,  alanine aminotransferase; T-Bil,  total biliru-
bin; PT-INR,  prothrombin time international ratio; AFP,  alpha fetoprotein; DCP,  des-gamma-carboxy prothrombin.
＊Statistically significant data.
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???? ?　 The survival rate according to the time and spread.  The 5-year survival rate of the patients who showed no recurrence within 2 
years after radical RFA was 78% (line “a”).  The 5-year survival rate of the patients who experienced recurrence within 2 years in another 
segment after RFA was 64% (line “b”).  The 5-year survival rate of the patients who experienced recurrence within 2 years in the same 
segment was 37% (line “c”).
model revealed that a high Child-Pugh score and early 
recurrence in the same segment were definite factors.
The 5-year survival rates according to the recurrence 
patterns of recurrence within 2 years in the same seg-
ment,  recurrence within 2 years in another segment,  
and no recurrence within 2 years were 37%,  64%,  and 
78% respectively (Fig. 2).
Factors associated with recurrence within two years 
in the same segment. To define the recurrence pat-
tern associated with poor outcomes,  we next investi-
gated the pre-RFA factors associated with the different 
recurrence patterns.  The patients who experienced 
recurrence within 2 years in the same segment showed 
lower albumin levels,  a higher Child-Pugh score,  larger 
tumor diameter,  and lower OXY levels than others 
(Table 4a).  A multivariate analysis was performed with 
these significant factors and the representative tumor 
marker AFP (Table 4b).  A large tumor diameter and 
low OXY levels were found to be factors associated with 
recurrence within 2 years in the same segment.
Discussion
In the present study,  we investigated the clinical 
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????? ??　 Recurrence within two years in the same segment or not
factors Recurrence within 2 years in the same segment others p-value
Number 44 191
Age (years) 71 (62-76) 69 (62-74) 0.442
Sex (M : F) 29 : 15 114 : 77 0.442
Baseline liver disease
　HCV : HBV : HBV+HCV : others 34 : 4 : 0 : 6 144 : 22 : 4 : 21 0.555
Ferritin (ng/ml) 118 (74-225) 125 (59-283) 0.786
Platelet (104/μl) 8.5 (7.3-13.1) 10.7 (7.2-15.3) 0.307
CRP (mg/dl) 0.21 (0.10-0.68) 0.20 (0.07-1.04) 0.254
AST (U/L) 45 (34-63) 45 (33-61) 0.849
ALT (U/L) 38 (28-51) 38 (25-55) 0.691
T-Bil (mg/dl) 0.91 (0.64-1.20) 0.74 (0.58-1.05) 0.103
Albumin (g/dl) 3.4 (3.2-3.9) 3.8 (3.4-4.1) 0.010＊
Creatinine (mg/dl) 0.71 (0.62-0.84) 0.75 (0.63-0.86) 0.281
PT-INR 1.03 (0.98-1.08) 0.98 (0.93-1.06) 0.054
Child-Pugh Score 6 (5-7) 5 (5-6) 0.015＊
AFP (ng/ml) 16 (6-91) 11 (5-37) 0.084
AFP-L3 (%) 0.5 (0-8.2) 0.5 (0-4.6) 0.333
DCP (mAU/ml) 36 (17-84) 27 (18-63) 0.506
Tumor diameter (mm) 18 (15-27) 16 (13-20) <0.001＊
Oxidative stress-related markers
　dROM (CARR U) 291 (248-350) 313 (275-359) 0.144
　OXY (μmol HClO/mL) 294 (262-330) 317 (287-352) 0.021＊
Values were indicated as median (25-75 percentile) unless otherwise noted.
HCV,  hepatitis C virus; HBV,  hepatitis B virus; CRP,  C-reactive protein; AST,  aspartate aminotransferase; ALT,  alanine aminotransfer-
ase; T-Bil,  total bilirubin; PT-INR,  prothrombin time international ratio; AFP,  alpha fetoprotein; DCP,  des-gamma-carboxy prothrombin,  
＊Statistically significant data.
????? ??　 Results of a multivariate analysis for recurrence within two years in the same segment or not
odds ratio 95% C.I. p-value
Child-Pugh Score (>5) 2.060 0.876-4.842 0.098
Tumor diameter (>16 mm)＊ 2.822 1.181-6.744 0.020＊
AFP (>10 ng/ml) 1.160 0.501-2.688 0.729
OXY (<314)＊ 2.416 1.006-5.801 0.049＊
AFP,  alpha fetoprotein; DCP,  des-gamma-carboxy prothrombin,  ＊Statistically significant data.
impact of oxidative stress-related conditions before rad-
ical ablation of HCC.  Poor survival was correlated with 
recurrence within 2 years in the same segment.  This 
poor outcome-related pattern of recurrence was associ-
ated with a large tumor and low OXY levels.  A highly 
maintained antioxidative function would be a necessary 
response after radical RFA.
Post-ablation HCC recurrence is a critical factor 
associated with poor survival.  Several reports have 
described the phenotype of early-recurring tumors.  
One study showed that progressive tumor cell pheno-
types with high positivity for the proliferation marker 
Ki-67 were predominant in post-RFA recurrence 
tumors in comparison to the initially resected tumors 
[22].  Oxidative-stress-related markers have also been 
involved as significant markers.  A genome-wide gene- 
expression profile of cancer tissue and the surrounding 
noncancerous liver tissue found that increased expres-
sion of the cytochrome P450 1A2 (CYP1A2) gene in 
noncancerous tissue was a predictive marker for non- 
recurrence [23].  CYP1A2 is a form of the hepatic cyto-
chrome P450 oxidative system that is involved in drug 
and cholesterol metabolism.  CYP1A2 knockout mice 
showed increased oxidative stress in liver microsomes,  
suggesting that CYP1A2 is an antioxidant molecule 
[24].  The plasma concentration of another antioxidant 
enzyme,  glutathione peroxidase 3 (GPx3),  has been 
investigated in resected HCC patients,  with the result 
that lower levels were predictive of tumor progression 
and tumor recurrence [25].  These data likely indicated 
that the antioxidant reservoir function in the adjacent 
liver is critical for achieving good survival,  as we found 
that antioxidant OXY levels were high in patients with a 
better prognosis.  OXY has been shown to be correlated 
with the serum albumin levels in chronic liver diseases 
patients,  suggesting that the antioxidant function 
depends on the liver reservoir function as shown in our 
present data [20].  The difference between resected 
patients and our present cases who underwent radical 
ablation is the persistence of the tumor-adjacent non-
cancerous area,  which was free in the resected patients.  
The tumor-adjacent area has been shown to have 
increased levels of antioxidant enzymes in colon cancer 
as well,  suggesting that an antioxidant response may be 
induced in the cancer-adjacent area [26].  The patients 
who achieved a better prognosis may have had a greater 
degree of antioxidant-related activity adjacent to their 
ablated cancers.
However,  antioxidant system activation in cancer 
cells enables them to escape from oxidative stress 
resulting in their survival.  Under oxidative-stress- 
inducing experimental conditions,  HCC cells could 
induce anti-oxidant defense system TRIM25-Nrf2 path-
way activation,  resulting in tumor cell survival [27].  
Oxidative stress should be maintained to damage cancer 
cells.  Recently,  the use of oxidative-stress-inducing 
agents has been suggested as a future strategy for man-
aging several cancers,  as in the use of high-dose ascor-
bic acid for treating gastric cancer [28],  colon cancer 
[29],  and pancreatic cancer [30].  Antioxidant activity is 
favorable in the tumor-adjacent normal liver; however,  
it is unfavorable in cancer cells.  One of the limitations 
of the present investigation was that the oxidative stress 
condition was investigated using only serum obtained 
just before RFA.  To accurately evaluate the oxidative 
stress condition,  a local oxidative-stress-related status 
analysis should be conducted with samples of the tumor 
and of the non-tumor surrounding tissue.  However,  
given that our subjects received RFA as a radical ther-
apy,  an insufficient number of specimens were 
obtained.  In the future,  liver tumor and adjacent tissue 
biopsy specimen analyses should be conducted.  In 
addition,  the time course of the oxidative stress-related 
markers was not investigated.  A prospective study 
should be conducted as the next step.
In our present study,  the oxidative stress marker 
dROM showed no correlation with post-RFA recur-
rence or survival.  dROM is considered to be a reliable 
indicator of circulating ROS [17 , 18].  Suzuki et al.  
reported that higher dROM was predictive of post- 
resection or post-RFA recurrence [31].  The number of 
patients included in the study was relatively small at 45 
patients,  20% (9 patients) of whom had multiple 
tumors.  In addition,  they defined the factors that pre-
dicted simple recurrence.  These differences from our 
present analysis might have resulted in the difference in 
the assessment of the dROM levels.
The segment of the resident HCC is at a high risk of 
recurrence because of the high likelihood of cancer cells 
from HCC spreading through the portal vein.  
Anatomic resection,  which involves the systematic 
removal of a hepatic segment,  has been indicated to be 
superior to local resection with respect to the risk of 
recurrence and the survival of HCC [32].  Recurrence in 
the same segment is a unique issue with local ablation 
therapy,  in contrast to anatomic resection.  To manage 
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this issue in cases of RFA treatment,  our present results 
suggest that oxidative stress should be maintained 
rather than eliminated.
OXY was positively correlated with the platelet 
count and albumin levels and negatively correlated with 
the total bilirubin level and Child-Pugh score.  
Similarly,  in our previous analysis of patients with 
NAFLD,  OXY showed a positive correlation with the 
platelet count and albumin levels [21].  OXY might 
reflect the liver reservoir function that would be neces-
sary for antioxidant power.
Recently,  many commercially available dietary anti-
oxidants have been marketed as having an “anticancer” 
effect.  However,  we must be aware that the physiologi-
cal induction of ROS is a natural response to defend 
cells from a toxic microbiome and is required for 
plasma membrane repair,  and especially in HCC 
patients,  it is an anticancer response that should be 
moderately maintained.  Given that antioxidant power 
was correlated with liver function reservoir markers,  
maintaining liver function is necessary to avoid 
poor-survival-related recurrence after RFA.
In conclusion,  the post-radical RFA survival was 
correlated with the Child-Pugh score and with recur-
rence within 2 years in the same segment.  This recur-
rence pattern was associated with a large tumor diame-
ter and low levels of the antioxidant reservoir marker 
OXY.  Maintaining the antioxidant reservoir function 
with high OXY values is favorable for long-term sur-
vival and to prevent recurrence within two years in the 
RFA-treated segment.
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